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Objectives The purpose of this study was to evaluate the impact of upgrading implantable cardioverter-defibrillator (ICD)
therapy to cardiac resynchronization therapy (CRT) combined with defibrillator (CRT-D) on the occurrence of ven-
tricular arrhythmia (VA) and appropriate ICD therapies.
Background CRT has been shown to improve left ventricular (LV) systolic function and induce reverse LV remodeling. In addi-
tion, it has been hypothesized that CRT may reduce the incidence of VA.
Methods Heart failure patients receiving an upgrade from ICD to CRT-D were evaluated. Patients were considered re-
sponders to CRT if LV end-systolic volume reduced 15% at 6 months of follow-up. Episodes of VA, triggering
device therapy (anti-tachycardia pacing and shocks) were recorded before and after upgrade for the overall pop-
ulation. In addition, these outcomes were compared between CRT responders and nonresponders during the
follow-up period after CRT response was assessed.
Results One hundred fifteen patients (93 males [81%], age 65  12 years) were evaluated during a mean follow-up of
54  34 months before CRT-D upgrade and 37  27 months after upgrade. In CRT responders (n  70), the
frequency of VA requiring appropriate device therapy demonstrated a trend toward a decrease from 0.51  0.79
to 0.30  0.59 per patient per year after CRT-D upgrade (p  0.052). In CRT nonresponders (n  45), the fre-
quency of VA requiring appropriate device therapy significantly increased from 0.40  0.69 to 1.21  2.53 per
patient per year after CRT-D upgrade (p  0.014).
Conclusions After upgrade from ICD to CRT-D, nonresponders to CRT showed a significant increase in VA burden requiring
appropriate device therapy. (J Am Coll Cardiol 2011;58:2282–9) © 2011 by the American College of Cardiol-
ogy Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.08.038Cardiac resynchronization therapy (CRT) has been demon-
strated to be an effective treatment in patients with ad-
vanced heart failure: it improves clinical symptoms, reduces
heart failure–related hospitalization rates, and improves
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2011, accepted August 23, 2011.long-term survival (1–4). These beneficial effects have been
related to left ventricular (LV) reverse remodeling after
CRT implantation. In addition, heart failure patients with a
low ejection fraction (EF) are at risk of sudden arrhythmic
death, and prophylactic implantable cardioverter-defibrillator
(ICD) implant is indicated for many of these patients (5,6).
However, the effects after upgrade from ICD to CRT-
defibrillator (CRT-D) on the occurrence of ventricular
arrhythmias (VAs) are controversial so far (7–10). Whereas
some studies have demonstrated a significant decrease in the
burden of VA along with significant LV reverse remodeling
(7,9), other studies have shown no reduction or even an
increase in the frequency of VA or appropriate ICD
therapies (8,10). In addition, the association between LV
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burden and frequency of appropriate ICD therapies is
unclear.
Patients who received an ICD may have heart failure
symptoms at follow-up. Upgrading these patients to CRT
has shown to improve clinical symptoms and LV function
(11). Importantly, this subgroup of patients provides a
unique opportunity to evaluate the effects of CRT-D
upgrade on the burden of VA. Accordingly, the present
evaluation assessed the impact of CRT-D upgrade on the
occurrence of VA and appropriate therapies. In addition,
the association between LV reverse remodeling and VA
burden was evaluated.
Methods
Patient population and data collection. Since 1996, data
from all patients who received an ICD device at the Leiden
University Medical Center were prospectively collected in
the departmental cardiology information system (EPD-
Vision, Leiden University Medical Center, Leiden, the
Netherlands). Characteristics at baseline and data from the
implant procedure and follow-up visits were recorded. For
the current analysis, ICD patients who underwent an
upgrade to CRT-D were selected.
The patient population consisted of consecutive patients
who underwent upgrade from single- or dual-chamber ICD
to CRT-D owing to progressive symptoms of heart failure.
Before upgrading to CRT-D, all patients underwent com-
plete clinical history, physical examination, 12-lead electro-
cardiography, and transthoracic echocardiography. Clinical
parameters included cardiovascular risk factors, renal func-
tion, New York Heart Association (NYHA) functional
class, quality-of-life score as assessed with the Minnesota
Living with Heart Failure Questionnaire and the 6-min
walk distance (12,13). Echocardiographic parameters in-
cluded LV dimensions and LVEF. At 6-month follow-up
after CRT-D upgrade, according to the current clinical
protocol, clinical status was reassessed, and a repeat trans-
thoracic echocardiogram was performed to evaluate LV
dimensions and systolic function. Patients were considered
responders if a reduction in left ventricular end-systolic
volume (LVESV) 15% was documented (14).
All patients were followed up from the ICD implantation
date until September 2010 for the occurrence of all-cause
mortality and appropriate therapies due to ventricular tachy-
cardia or ventricular fibrillation. Arrhythmia burden was
calculated from the total number of episodes divided by the
total number of years of ICD or CRT-D and presented in
patient per year basis. These endpoints were prospectively
recorded during 2 correlative follow-up periods. The first
follow-up period was from the ICD implantation date to
the CRT-D upgrade date and from the CRT-D upgrade
date until the latest device interrogation follow-up. Changes
in number of appropriate therapies and shocks after CRT-D
upgrade were evaluated for the overall population. There-fore, each patient served as his or
her own control for comparison
of frequency of appropriate ther-
apies and shocks before and after
CRT-D upgrade. The second
follow-up period was from the
evaluation of response to CRT-D
(at 6-month follow-up) until the
last device interrogation follow-up.
The incidence of appropriate ther-
apies and shocks and arrhythmia
burden after CRT-D upgrade
were then compared between re-
sponders and nonresponders to
CRT-D.
Device implantation and settings.
Eligibility for ICD implantation
in this population was based on
international guidelines for pri-
mary and secondary prevention
(5,6). Upgrade to CRT-D was
performed according to current
guidelines: advanced symptoms
of heart failure despite optimized
medical therapy, LVEF 35%, and a wide QRS complex
(120 ms) (15).
Implantation of defibrillator systems was performed
transvenously, with conventional right atrial and ventricular
leads positioning. During CRT-D implantation, the LV
lead was inserted through the subclavian vein followed by
cannulation of the coronary sinus. Subsequently, the LV
pacing lead was inserted through the coronary sinus with
the help of an 8-F guiding catheter and positioned as far as
possible in the venous system, preferably in a (postero)
lateral vein. Implanted systems were manufactured by
Biotronik (Berlin, Germany), Boston Scientific (Natick,
Massachusetts, formerly CPI, Guidant, St. Paul, Minne-
sota), Medtronic (Minneapolis, Minnesota), and St. Jude
Medical/Ventritex (St. Paul, Minnesota).
Defibrillators were programmed as follows: a VA monitor
zone was programmed in all patients (150 to 188 beats/
min). No therapy was programmed in this zone until
arrhythmias were detected during follow-up. Any VA faster
than 188 beats/min was initially attempted to be terminated
with 2 bursts of antitachycardia pacing and, after continu-
ation of the arrhythmia, device shocks were the indicated
therapy. A VA 210 beats/min was directly attempted to
be terminated by device shocks. Furthermore, atrial arrhyth-
mia detection was set to 170 beats/min with supraven-
tricular arrhythmia discriminators enabled. Settings were
adapted, only if clinically indicated (e.g., hemodynamic
well-tolerated ventricular tachycardia at high rate; ventric-
ular tachycardia in the monitor zone).
Echocardiography. Transthoracic echocardiography was
performed with the patients in left lateral decubitus position
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ment (M4S Probe, Vivid 7, GE-Vingmed, Horten, Nor-
way). All images were digitally stored on hard disks for
offline analysis (EchoPAC version 108.1.5, GE-Vingmed).
The LVESV, left ventricular end-diastolic volume (LVEDV),
and LVEF were measured from the apical 2- and 4-chamber
views using the modified biplane Simpson’s method (16).
As previously described, response to CRT was defined by
15% reduction in LVESV at 6-month follow-up as
compared with baseline echocardiogram (before CRT-D
upgrade) (14).
Follow-up and definition of endpoints. Patients who
were lost to follow-up or who died before the 6-month
echocardiography after CRT-D upgrade were excluded
from the analyses. All remaining patients were followed up
in the ICD clinic at 3- to 6-month intervals. Occurrences of
appropriate, successful ICD therapies were recorded as
events. During device interrogation, episodes were assessed
for appropriate ICD therapy (antitachycardia therapies or
shocks) and verified by an electrophysiologist. Shocks were
classified as appropriate when they occurred in response to
ventricular tachyarrhythmia or ventricular fibrillation. Elec-
trical storm was defined as 3 or more therapies for ventric-
ular tachyarrhythmias within 24 h (17).
The burden of VA requiring ICD therapy or shock was
determined by calculating the number of episodes per
patient per year. The ICD therapies delivered within 24 h
after the previous therapy were not included for the analysis
of the burden of VA. Separate analyses for appropriate
shocks only and for appropriate therapies (including appro-
priate shock and antitachycardia pacing) were performed.
Statistical analysis. For reasons of uniformity, summary
statistics for all continuous variables are expressed as mean
and standard deviation. Dichotomous data are presented as
numbers and percentages. The Kolmogorov-Smirnov test
was used to evaluate the distribution of continuous data.
The Student t test was used to compare continuous data
normally distributed whereas the Mann-Whitney U test was
used to compare continuous data nonnormally distributed.
Categorical variables were compared with the chi-square
test (when no cells had an expected frequency 5) and
Fisher’s exact test (when 1 or more cells had an expected
frequency 5). Comparisons of continuous data at baseline
and at 6-month follow-up were performed with a paired
Student t test (when data distribution was normal) or
Wilcoxon signed-rank test (for continuous data non-
normally distributed). Specifically, changes in NYHA func-
tional class between baseline and 6-month follow-up were
evaluated with Wilcoxon signed-rank test because this
parameter followed a non-normal distribution whereas
changes in other clinical parameters (quality of life and
6-min walk test) and echocardiographic parameters of LV
function and volumes were compared with a paired Student
t test. Variables related to VA burden and appropriate ICD
therapies and shocks were not normally distributed, andtherefore, changes between baseline and 6 months were
evaluated with the Wilcoxon signed-rank test.
Cumulative event rates from the date of CRT-D upgrade
until the last follow-up were calculated using the Kaplan-
Meier method. The log-rank tests for time-to-event data
with respect to the endpoints (appropriate shocks and
appropriate therapies) were used for statistical comparison
between the 2 patient groups dichotomized based on re-
sponse to CRT at 6-month follow-up. Univariate and
multivariate Cox proportional-hazards models were con-
structed to identify independent determinants of the end-
points (appropriate therapies and appropriate shocks) after
CRT-D upgrade. All independent variables with a
p value 0.25 were retained in the multivariate model. In
addition, ventricular tachycardia (VT) ablation was entered
as a time-dependent covariate. A p value of 0.05 was
considered significant. All statistical analyses were per-
formed with SPSS software (version 18.0, SPSS, Chicago,
Illinois).
Results
Patient population. A total of 123 patients underwent a
successful CRT-D upgrade because of worsening symptoms
of heart failure. Eight patients who were lost to follow-up
(n  2, 2%) or who died (n  6, 5%) before the 6-month
echocardiography after CRT-D upgrade were excluded
from the analysis. Consequently, 115 patients were included
in the analysis with a mean follow-up of 54  34 months
after ICD implantation and an additional mean follow-up
of 37  27 months after CRT-D upgrade. Demographic,
clinical, and echocardiographic characteristics before
CRT-D upgrade are summarized in Table 1. Mean age was
65  12 years, and 92 (80%) patients were male. Ischemic
heart failure etiology was recorded in the majority of the
patients (75%). Most patients had NYHA functional class
III heart failure symptoms (93%) and a severely depressed
LV function, with a mean LVEF of 26  8%. Mean QRS
duration was 167  35 ms. Finally, medical therapy
included angiotensin-converting enzyme inhibitors (90%),
diuretics (85%), beta-blockers (77%), and amiodarone
(40%). During the entire follow-up of the study (from ICD
implantation to last follow-up after CRT-D upgrade), 21
(18%) patients underwent successful VT ablation, and 11
(10%) patients underwent successful atrioventricular junc-
tional ablation. Seventeen (81%) and 4 (19%) patients
underwent VT ablation before and after CRT-D,
respectively.
6-month follow-up after CRT-D upgrade. CLINICAL AND
ECHOCARDIOGRAPHIC PARAMETERS. At 6-month
ollow-up after CRT-D upgrade, a significant improvement
n clinical status and LV volumes and LVEF was observed
n the overall population. The NYHA functional class
mproved from 3.1  0.3 to 2.3  0.7 (p  0.001) and
quality-of-life score decreased from 36  18 to 29  17
(p  0.001). In addition, the 6-min walk distance increased
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November 22, 2011:2282–9 Impact of ICD Upgrade to CRT-Dfrom 320  129 m to 372  138 m (p  0.001). In the
overall population, the LVESV and LVEDV reduced sig-
nificantly (from 168  66 ml to 143  61 ml, p  0.001;
from 223  76 ml to 204  72 ml, p  0.001, respectively)
with a significant increase in LVEF (from 26 8% to 31 9%,
p  0.001).
Appropriate device therapy burden before and after
CRT-D upgrade in the overall population. During the
time elapsed between ICD implantation and CRT-D up-
grade (54  34 months), 59 (51%) patients received
Patient Characteristics at CRT-D Upgrade (N  115)Table 1 Patient Characteristics at CRT-D Upgrade (N  115)
Age, yrs 65 12
Male 93 (81)
Primary prevention indication 35 (30)
QRS duration, ms 167 35
History of atrial fibrillation 24 (21)
Renal clearance, ml/min 63 34
Ischemic heart disease 86 (75)
NYHA functional class
III 107 (93)
IV 8 (7)
6-min walk test, m 312 130
Quality-of-life score 37 18
LVEDV, ml 225 79
LVESV, ml 169 67
LVEF, % 26 8
Device type
Single-chamber 36 (31)
Dual-chamber 79 (69)
Medication
Amiodarone 46 (40)
Anticoagulants 100 (87)
Diuretics 98 (85)
ACE inhibitors/AT II antagonist 104 (90)
Beta-blocker 89 (77)
Spironolactone 54 (47)
Values are mean  SD or n (%).
ACE  angiotensin-converting enzyme; AT  angiotensin; CRT-D  cardiac resynchronization
therapy-defibrillator; LVEDV left ventricular end-diastolic volume; LVEF left ventricular ejection
fraction; LVESV  left ventricular end-systolic volume; NYHA  New York Heart Association.
Clinical and Echocardiographic Parameters at 6-Month Follow-Up inTable 2 Clinical and Echocardiographic Parameters at 6-Month
Parameters
Responders
Baseline 6 Months
NYHA functional class
I 0 10 (13)
II 0 39 (52)
III 71 (95) 25 (33)
IV 4 (5) 1 (1)
6-min walk test, m 339 137 382 146
QoL score 36 18 29 17
LVEDV, ml 227 72 190 65
LVESV, ml 172 62 128 51
LVEF, % 25 9 33 9Values are n (%) or mean  SD. Outcomes were calculated with a paired Student t test unless indicated
QoL  quality of life; other abbreviations as in Table 1.appropriate therapies. The total number of appropriate therapies
was 11  50 per patient and the burden of VA was 0.46 
0.75 per patient per year. The appropriate ICD shock
burden was 0.36  0.77 per patient per year. A total of 8
(7%) patients experienced an electrical storm before
CRT-D upgrade. Of the 59 patients receiving appropriate
device therapy before CRT-D upgrade, 9 (15%) patients
underwent VT ablation. Cumulative incidence of device
therapy was 29% (95% confidence interval [CI]: 21% to
37%) after 1 year, 36% (95% CI: 27% to 45%) after 2 years,
and 56% (95% CI: 45% to 66%) after 5 years. After CRT-D
upgrade, 49 (43%) patients experienced appropriate thera-
pies during an additional mean follow-up of 37  27
months. The total number of appropriate therapies reduced
to 5  17 per patient, although this change was not
statistically significant (p  0.119). In addition, the fre-
quency of VA (0.66  1.70 per patient per year, p  0.775)
nd appropriate ICD shocks (0.52  3.01 per patient per
ear, p  0.218) remained unchanged. A total of 8 (7%)
atients experienced an electrical storm after CRT-D up-
rade. Of the 49 patients receiving appropriate device
herapy after CRT-D upgrade, 11 (22%) patients under-
ent VT ablation. Cumulative incidence of device therapy
as 25% (95% CI: 17% to 34%) after 1 year, 34% (95% CI:
5% to 44%) after 2 years, and 62% (95% CI: 49% to 75%)
fter 5 years. Finally, a total of 34 (30%) patients died after
RT-D upgrade.
hanges in appropriate device therapy burden after
RT-D upgrade according to the echocardiographic
esponse. On the basis of a reduction of LVESV 15% at
-month follow-up after CRT-D upgrade, 70 (61%) pa-
ients were responders. Table 2 summarizes the changes in
linical status and echocardiographic parameters at 6-month
ollow-up after CRT-D upgrade for both groups of pa-
ients, responders and nonresponders.
In the group of responders, the percentage of patients
ho received appropriate device therapies decreased from
4% to 33% after CRT-D upgrade. In addition, the total
umber of appropriate device therapies also decreased from
ponders and Nonresponders to CRT-Dw-Up in Responders and Nonresponders to CRT-D
Nonresponders
Value Baseline 6 Months p Value
0.001 0.211
0 4 (9)
0 22 (49)
41 (91) 17 (38)
4 (9) 2 (4)
0.009 291 113 357 124 0.001
0.001 36 17 27 17 0.005
0.001 216 82 223 77 0.113
0.001 163 72 164 67 0.879
0.001 26 7 27 8 0.140ResFollo
p



otherwise (*chi-square test).
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Furthermore, the frequency of VA requiring appropriate
device therapy demonstrated a trend toward a decrease from
0.51  0.79 to 0.30  0.59 per patient per year after
RT-D upgrade (p  0.052) (Fig. 1). Interestingly, the
requency of appropriate device shocks reduced significantly
rom 0.21  0.32 to 0.11  0.33 per patient per year (p 
.009) (Fig. 1). Furthermore, in the group of responder
atients to CRT, 3 (4%) patients experienced an electrical
torm and 12 (17%) patients underwent VT ablation. In the
roup of patients who did not show response to CRT, the
ercentage of patients who received appropriate device
herapies was 47% before CRT-D upgrade and 58% after
RT-D upgrade. In these patients, the total number of
ppropriate device therapies per patient was 8  22 before
RT-D upgrade and 10  25 after CRT-D upgrade. In
ddition, the frequency of appropriate device shocks re-
ained unchanged after CRT-D upgrade (from 0.24 
.52 to 0.46 1.23 per patient per year, p 0.333) (Fig. 1). In
ontrast, the frequency of VA significantly increased from
.40  0.69 per patient per year before CRT-D upgrade to
.21 2.53 per patient per year after CRT-D upgrade (p
.014) (Fig. 1). In the nonresponder patients group, 5 (11%)
atients experienced an electrical storm and 9 (20%) pa-
ients underwent VT ablation.
redictors of combined endpoint after CRT-D upgrade.
igure 2 shows the Kaplan-Meier estimates of the com-
ined endpoint (appropriate ICD therapies) for responder
nd nonresponder patients after CRT-D upgrade. The
umulative incidence for appropriate ICD therapy in the
roup of responder patients was 19% (95% CI: 9% to 29%)
fter 1 year, 29% (95% CI: 17% to 41%) after 2 years, and
1% (95% CI: 33% to 69%) after 5 years. In contrast, in the
roup of nonresponders, a significantly higher cumulative
ncidence of 34% (95% CI: 20% to 48%) after 1 year, 42%
95% CI: 27% to 57%) after 2 years, and 76% (95% CI: 59%
o 93%) after 5 years was observed (log-rank p  0.017).
Regarding appropriate ICD shocks, cumulative inci-
Figure 1 Changes in Appropriate ICD Therapy and ICD Shocks
Changes in the number of episodes of appropriate implantable cardioverter-defibri
in responders and nonresponders to cardiac resynchronization therapy. Solid barsences in responder patients at 1, 2, and 5 years of follow-upere 9% (95% CI: 1% to 16%), 13% (95% CI: 4% to 23%),
nd 26% (95% CI: 12% to 40%), respectively. In contrast,
he group of nonresponders showed significantly higher
umulative incidences of ICD shocks: 23% (95% CI: 11% to
6%) after 1 year, 32% (95% CI: 17% to 47%) after 2 years,
nd 66% (95% CI: 45% to 88%) after 5 years (log-rank p 
.001) (Fig. 3).
On multivariate Cox regression analysis, response to
RT defined as reduction in LVESV 15% was indepen-
ently associated with lower risk of appropriate ICD ther-
pies (hazard ratio: 0.439, 95% CI: 0.245 to 0.786, p 
.001) (Table 3) and ICD shocks (hazard ratio: 0.354, 95%
I: 0.167 to 0.750, p  0.007) (Table 4).
iscussion
he findings of the present study can be summarized as
ollows: 1) “upgrade” of ICD to CRT-D did not result in a
ignificant change in the frequency of appropriate ICD
herapies and shocks in the overall population; 2) responder
ICD) therapy (left) and appropriate ICD shocks (right) per patient per year
eline; open bars  follow-up.
Figure 2 Kaplan-Meier Curve for Appropriate ICD Therapy
Kaplan-Meier curve for appropriate implantable cardioverter-defibrillator (ICD)
therapy in responders (broken line) and nonresponders (solid line) after
cardiac resynchronization therapy upgrade.llator (
 bas
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November 22, 2011:2282–9 Impact of ICD Upgrade to CRT-Dpatients to CRT-D (with a significant reduction in LVESV
at 6-month follow-up) demonstrated a trend toward a
reduction in the frequency of appropriate device therapies
and a significant reduction in the frequency of appropriate
device shocks; and 3) in contrast, patients who did not show
response to CRT had a significant increase in the frequency
of VA requiring device therapy.
Effect of CRT-D upgrading on the occurrence of VA. In
the present study, the overall population showed significant
clinical and echocardiographic improvements at 6-month
follow-up after CRT. These findings are in line with
previous studies in which CRT was associated with an
improved clinical and echocardiographic outcome in heart
failure patients (12). Interestingly, these improvements in
clinical status and LV systolic performance was not accom-
panied by a significant change in the number of appropriate
ICD therapies or the burden of ICD shocks.
The effects of CRT upgrade on VA have remained
controversial, so far. In a study by Ermis et al. (7), in which
18 consecutive ICD patients underwent an “upgrade” to
CRT-D, the frequency of arrhythmias and number of
appropriate device therapies were reduced after CRT-D
Cox Proportional Hazard Ratio Model to PredictTable 3 Cox Proportional Hazard Ratio Mod
Univaria
HR 95% C
Male 1.011 0.472–2.1
NYHA functional class 1.451 0.443–4.7
Ischemic cardiomyopathy 0.675 0.362–1.2
Creatinine clearance, ml/min 1.001 0.993–1.0
Amiodarone 0.632 0.347–1.1
Response to CRT 0.509 0.290–0.8
Interim successful VT ablation 1.375 0.487–3.8
*Variable was included in multivariate analysis.
Figure 3 Kaplan-Meier Curve for Appropriate ICD Shock
Kaplan-Meier curve for appropriate implantable cardioverter-defibrillator (ICD)
shock in responders (broken line) and nonresponders (solid line) after cardiac
resynchronization therapy upgrade.CI confidence interval; CRT  cardiac resynchronization therapy; HR  h
York Heart Association; VT  ventricular tachycardia.implantation. The appropriate shock burden in these 18
patients was 0.58  1.02 per patient per year before CRT
and declined significantly (p  0.05) to 0.04  0.19 per
patient per year after CRT. Similar results were found in the
study by Kiès et al. (9), in which 17 consecutive ICD
patients underwent an “upgrade” to CRT-D. In that study,
VA number was significantly (p 0.01) reduced from 0.92 2.2
episodes per patient per month to 0.12  0.2 episodes per
patient per month after CRT-D upgrading. Permanent
biventricular pacing has been proposed as 1 of the mecha-
nisms to reduce the frequency of VA requiring ICD
therapy. During permanent biventricular pacing, the ven-
tricular conduction delay is reduced, leading to a decrease
in the occurrence of reentry, avoidance of pause-dependent
tachyarrhythmias, and reduction in the circulating levels of
norepinephrine, all known mechanisms that may trigger VA
(18,19). Conversely, however, both basic science and clinical
studies have shown a proarrhythmic effect of biventricular
pacing due to a reversed direction of activation of the left
ventricular wall. This reversal of the normal activation
sequence may prolong the QT interval and increase the
existing transmural dispersion of repolarization, creating the
substrate and trigger for reentrant arrhythmias (20).
Interestingly, in the MIRACLE-ICD (Multicenter In-
Sync ICD Randomized Clinical Evaluation) trial, the oc-
currence of appropriate ICD therapies or shocks in the
group of patients who received CRT-D did not show a
significant reduction (21). In this trial, a total of 369
patients with moderate to severe heart failure symptoms and
wide QRS complex were randomly allocated to a biventricu-
lar ICD group (CRT on) or to an ICD only group (CRT
off). There were no significant differences between groups
with respect to the occurrence of appropriate therapies
and/or appropriate shocks, despite improved quality of life,
functional status, and exercise capacity in the CRT group
(21). In addition, in the REVERSE (Resynchronization
Reverses Remodeling in Systolic Left Ventricular Dysfunc-
tion) study, in which 508 patients with mild heart failure
were randomly assigned to activated CRT (CRT on) and
activated ICD (CRT off), the estimated event rate for a first
treated VA episode was not significantly different between
opriate ICD TherapiesPredict Appropriate ICD Therapies
Multivariate
p Value HR 95% CI p Value
0.978 — — —
0.539 — — —
0.215* 0.522 0.273–0.999 0.049
0.740 — — —
0.135* 0.598 0.323–1.110 0.107
0.019* 0.439 0.245–0.786 0.001
0.548 — — —Apprel to
te
I
63
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53
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85azard ratio; ICD implantable cardioverter-defibrillator; NYHA  New
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Impact of ICD Upgrade to CRT-D November 22, 2011:2282–9the 2 groups after the 2-year follow-up period (18.7% in the
CRT-on group vs. 21.9% in the CRT-off group, p  0.84)
22). The event rates observed in the REVERSE study are
ignificantly lower as compared to the results of the present
tudy. However, it must be noted that in the REVERSE
tudy, only subjects with mild heart failure were included and
herefore the reported outcomes may not necessarily apply to
atients with more severe symptoms of heart failure as were
hose included in the current analysis. The presence of more
dvanced heart failure status with dilated left ventricles may be
ssociated with an increased likelihood of VA requiring device
herapy (10). On the basis of this assumption, it can be
ypothesized that patients with LV reverse remodeling after
RT may show a significant reduction in the incidence of VA
hen compared with the patients who do not show LV reverse
emodeling after CRT.
evice therapy in responders and nonresponders. Gold
t al. (22), showed that the antiarrhythmic effect of CRT
ould be explained by induction of a favorable LV reverse
emodeling and decreased myocardial wall tension and
lectrical stabilization of the myocyte membranes. In the
resent study, the group of responders to CRT showed a
rend toward a reduction in the number of appropriate
evice shocks after CRT upgrading. In the REVERSE
tudy, in which the patients from the CRT-on group who
howed LV reverse remodeling had a decrease in the
ncidence of VA compared with patients who did not
ave such a favorable reverse remodeling (5.6% vs. 16.3%;
azard ratio: 0.31, p  0.001) (22). These findings may
onfirm the hypothesis of Gold et al. (22) in that the
mprovement in LV dimensions and function, accompanied by
reduction in wall tension, results in a decreased arrhythmo-
enicity of the myocardium and reducing ICD therapy in
esponders to CRT-D (after upgrade). Additional studies are
arranted to elucidate how much LV reverse remodeling is
eeded to minimize the number of appropriate ICD therapies
n patients who were upgraded to CRT.
tudy limitations. This was a retrospective observational
nalysis of prospectively assessed data evaluating the occur-
ence of VA requiring appropriate device therapy in a cohort
f patients before and after CRT-D upgrade. Because
Cox Proportional Hazard Ratio Model to PredictTable 4 Cox Proportional Hazard Ratio Mod
Univaria
HR 95% C
Male 1.066 0.437–2.5
NYHA functional class 2.004 0.604–6.6
Ischemic cardiomyopathy 0.977 0.437–2.1
Creatinine clearance, ml/min 0.991 0.977–1.0
Amiodarone 0.874 0.424–1.8
Response to CRT 0.319 0.153–0.6
Interim successful VT ablation 2.038 0.702–5.9
*Variable was included in multivariate analysis.
Abbreviations as in Table 3.atients received ICDs in a single center over a long periodf time, evolving guidelines may result in a heterogeneous
opulation. Furthermore, few patients had multiple device
herapies within 24 h after the previous therapy. These
pisodes were not counted for analysis of the burden of VA. In
ddition, since all CRT-D devices had antitachycardia treat-
ent function and the oldest implanted ICD devices did not
ave this function, the number of appropriate shocks in the
CD group might be overestimated when compared with the
RT-D group. To date, definition of response to CRT is still
debated issue. In the present evaluation, a cut-off value of
5% reduction in LVESV was used to divide the patient
opulation into responders and nonresponders to CRT. Using
he median value of LVESV reduction at 6-month follow-up
ould be a valuable option to dichotomize the population. In
he present evaluation, however, this value was 17%, and the
nalysis based on the median reduction in LVESV yielded
imilar results. In addition, further studies are needed to
valuate whether LV reverse remodeling occurs beyond
-month follow-up after CRT-D upgrade, and whether that
ay result in further reduction in VA burden.
onclusions
n this large single-center study, the frequency of VA
equiring appropriate device therapy did not significantly
hange in the overall population after upgrade of ICD to
RT-D. Most important, however, in the subgroup of
atients who showed echocardiographic response to CRT at
-month follow-up (reduction in LVESV 15%), a trend
oward a reduction in the frequency of appropriate device
herapies and a significant reduction in the frequency of
ppropriate device shocks was observed. Moreover, echo-
ardiographic nonresponders after CRT-D had a significant
ncrease in the frequency of VA requiring device therapy
hen compared to the period before CRT.
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opriate ICD ShocksPredict Appropriate ICD Shocks
Multivariate
p Value HR 95% CI p Value
0.889 — — —
0.256 — — —
0.956 — — —
0.174* 0.993 0.980–1.007 0.326
0.715 — — —
0.002* 0.354 0.167–0.750 0.007
0.190* 1.987 0.683–5.783 0.208Apprel to
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